Guido Bellezza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5428546/publications.pdf

Version: 2024-02-01

46 804 18 26 papers citations h-index g-index

46 46 46 1416
all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy, 2022, 10, 291-300.	1.0	1
2	INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer. Journal of Cancer, 2021, 12, 3781-3795.	1.2	8
3	Type A thymoma invading the trachea: a case report. Mediastinum, 2021, 5, 0-0.	0.6	1
4	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Genes, 2021, 12, 273.	1.0	14
5	Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 4403.	1.8	24
6	Current Challenges for IDO2 as Target in Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 679953.	2.2	24
7	Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Genes, 2021, 12, 679.	1.0	25
8	Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. Human Vaccines and Immunotherapeutics, 2021, 17, 2972-2980.	1.4	5
9	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes, 2021, 12, 992.	1.0	5
10	Impact of Epithelial–Mesenchymal Immunophenotype on Local Aggressiveness in Papillary Thyroid Carcinoma Invading the Airway. Journal of Clinical Medicine, 2021, 10, 4351.	1.0	0
11	Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS ONE, 2021, 16, e0255580.	1.1	6
12	The implementation of a commercially available multi-gene profile test for breast cancer characterization in a department of pathology: what have we learned from the first 100 cases?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1079-1087.	1.4	3
13	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine., 2021, 9, e002179.		6
14	PLA2R Immunohistochemistry Staining in Membranous Glomerulopathy: A Challenging Stain to Interpret But a Potentially Useful Diagnostic Tool. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 414-421.	0.6	2
15	Cholesterol crystals tubulointerstitial injury during nephrotic syndrome; can be classified as tubular crystallopathy?. Journal of Nephropathology, 2021, 10, e20-e20.	0.1	1
16	Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With ¹⁸ F-FDG-PET/CT. Anticancer Research, 2020, 40, 3355-3360.	0.5	8
17	Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. Frontiers in Immunology, 2020, 11, 839.	2.2	28
18	Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor. Journal of Medicinal Chemistry, 2020, 63, 3701-3712.	2.9	27

#	Article	IF	Citations
19	Garcinoic acid prevents \hat{l}^2 -amyloid ($\hat{Al^2}$) deposition in the mouse brain. Journal of Biological Chemistry, 2020, 295, 11866-11876.	1.6	18
20	Primary angiosarcoma of the kidney: case report and comprehensive literature review. Open Medicine (Poland), 2019, 14, 443-455.	0.6	5
21	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 159-168.	1.4	27
22	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Medical Oncology, 2018, 35, 72.	1,2	29
23	KRAS mutation and DNA repair and synthesis genes in nonâ€'smallâ€'cell lung cancer. Molecular and Clinical Oncology, 2018, 9, 689-696.	0.4	7
24	Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clinical Drug Investigation, 2018, 38, 983-987.	1.1	14
25	Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276.	1.8	24
26	Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget, 2018, 9, 27346-27362.	0.8	20
27	Mitotic index matter: how to improve the assessment of mitosis in order to better classify G2 breast cancer and luminal A category. Histology and Histopathology, 2018, 33, 81-88.	0.5	1
28	Glyoxalase 2 drives tumorigenesis in human prostate cells in a mechanism involving androgen receptor and p53â€p21 axis. Molecular Carcinogenesis, 2017, 56, 2112-2126.	1.3	29
29	Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of $\hat{l}\pm$ -tocopherol (vitamin E). Journal of Nutritional Biochemistry, 2017, 47, 120-131.	1.9	40
30	Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα. Prostate, 2017, 77, 196-210.	1.2	47
31	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87.	0.9	19
32	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine, 2016, 10, 53-68.	1.0	56
33	IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast. International Journal of Surgical Pathology, 2016, 24, 37-42.	0.4	15
34	Future options for ALK-positive non-small cell lung cancer. Lung Cancer, 2015, 87, 211-219.	0.9	50
35	An Additional Case of Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma. International Journal of Surgical Pathology, 2015, 23, 217-220.	0.4	29
36	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. Lung Cancer, 2015, 90, 255-260.	0.9	43

#	Article	IF	CITATIONS
37	High expression of cellular retinol binding protein-1 in lung adenocarcinoma is associated with poor prognosis. Genes and Cancer, 2015, 6, 490-502.	0.6	16
38	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for <i>KRAS</i> mutant tumors. Oncotarget, 2015, 6, 32368-32379.	0.8	25
39	Localized Intrasplenic Mesothelioma. International Journal of Surgical Pathology, 2014, 22, 451-455.	0.4	6
40	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Nonâ€"Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. Clinical Lung Cancer, 2014, 15, 86-92.	1.1	40
41	CD10 is frequently expressed in classical seminomas. Histology and Histopathology, 2014, 29, 101-6.	0.5	3
42	Schwannoma of the breast: a case report and review of the literature. Tumori, 2007, 93, 308-11.	0.6	11
43	Coexpression of HER-2/neu and p53 in Breast Cancer Identifies a Subset with an Aggressive Biopathological Profile. Tumori, 2006, 92, 412-415.	0.6	4
44	Inflammatory myofibroblastic tumor of the larynx with anaplastic lymphoma kinase (ALK) protein overexpression. A case report. Tumori, 2006, 92, 449-51.	0.6	3
45	Ectopic prostatic tissue in the bladder. International Journal of Urology, 2005, 12, 1066-1068.	0.5	19
46	Pigmented "Black―Pheochromocytoma of the Adrenal Gland: A Case Report and Review of the Literature. Archives of Pathology and Laboratory Medicine, 2004, 128, e125-e128.	1.2	16